BIOMAT Database Logo BIOMAT Database Logo

Recombinant granulocyte-macrophage colony stimulating factor followed by immunosuppressive therapy for aplastic anaemia. 1993

K Doney, and R Storb, and F R Appelbaum, and C D Buckner, and J Sanders, and J Singer, and J A Hansen
Fred Hutchinson Cancer Research Center, Veterans Affairs Medical Center, Seattle, Washington 98104.

Seventeen patients with aplastic anaemia were treated with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) for 14 d. Nonresponding patients were then treated with anti-human thymocyte globulin (ATG), methylprednisolone and oxymetholone. Side-effects of rhGM-CSF included fever, nausea and vomiting, diarrhoea, bone pain, headache and chills. Two patients had sustained trilineage haemopoietic recovery after receiving only rhGM-CSF. Of 11 patients who received immunosuppressive therapy, there was one complete response, two partial responses, one minimal response, and seven nonresponses. Actuarial survival at 2 years is 64%. Early administration of rhGM-CSF had no apparent effect on subsequent response to immunosuppressive therapy.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

K Doney, and R Storb, and F R Appelbaum, and C D Buckner, and J Sanders, and J Singer, and J A Hansen
Successful treatment of gold-induced aplastic anaemia with granulocyte macrophage colony stimulating factor.
June 1992, British journal of rheumatology,
K Doney, and R Storb, and F R Appelbaum, and C D Buckner, and J Sanders, and J Singer, and J A Hansen
Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor.
February 1989, Blood,
K Doney, and R Storb, and F R Appelbaum, and C D Buckner, and J Sanders, and J Singer, and J A Hansen
Clinical experience with recombinant human granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor.
April 1989, Seminars in hematology,
K Doney, and R Storb, and F R Appelbaum, and C D Buckner, and J Sanders, and J Singer, and J A Hansen
Treatment of severe aplastic anemia with an immunosuppressive agent plus recombinant human granulocyte-macrophage colony-stimulating factor and erythropoietin.
November 1998, American journal of hematology,
K Doney, and R Storb, and F R Appelbaum, and C D Buckner, and J Sanders, and J Singer, and J A Hansen
Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor.
December 1988, The New England journal of medicine,
K Doney, and R Storb, and F R Appelbaum, and C D Buckner, and J Sanders, and J Singer, and J A Hansen
Effects of recombinant human granulocyte-macrophage colony-stimulating factor as treatment for aplastic anemia and agranulocytosis.
January 1990, Progress in clinical and biological research,
K Doney, and R Storb, and F R Appelbaum, and C D Buckner, and J Sanders, and J Singer, and J A Hansen
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1).
July 1992, The New England journal of medicine,
K Doney, and R Storb, and F R Appelbaum, and C D Buckner, and J Sanders, and J Singer, and J A Hansen
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2).
July 1992, The New England journal of medicine,
K Doney, and R Storb, and F R Appelbaum, and C D Buckner, and J Sanders, and J Singer, and J A Hansen
Recombinant human granulocyte-macrophage colony-stimulating factor produces fever.
April 1988, Lancet (London, England),
K Doney, and R Storb, and F R Appelbaum, and C D Buckner, and J Sanders, and J Singer, and J A Hansen
Recombinant human granulocyte-macrophage colony-stimulating factor in AIDS.
March 1988, The New England journal of medicine,
Copied contents to your clipboard!